Glycogen phosphorylase inhibitors

Type 2 diabetes is a complex metabolic disease with hyperglycemia as its recognizable hallmark. Hepatic glucose output is elevated in Type 2 diabetic patients, and evidence suggests drugs which lower hepatic glucose production are effective antihyperglycemic agents. Glycogenolysis, which is the rele...

Full description

Saved in:
Bibliographic Details
Published inMini reviews in medicinal chemistry Vol. 6; no. 8; p. 845
Main Authors Henke, Brad R, Sparks, Steven M
Format Journal Article
LanguageEnglish
Published Netherlands 01.08.2006
Subjects
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - enzymology
Enzyme Inhibitors - pharmacology
Enzyme Inhibitors - therapeutic use
Glucose - metabolism
Glycogen - metabolism
Glycogen Phosphorylase - antagonists & inhibitors
Humans
Hyperglycemia - drug therapy
Hyperglycemia - enzymology
Hypoglycemic Agents - pharmacology
Hypoglycemic Agents - therapeutic use
Liver - drug effects
Liver - metabolism
Online AccessGet more information

Cover

More Information
Summary:Type 2 diabetes is a complex metabolic disease with hyperglycemia as its recognizable hallmark. Hepatic glucose output is elevated in Type 2 diabetic patients, and evidence suggests drugs which lower hepatic glucose production are effective antihyperglycemic agents. Glycogenolysis, which is the release of monomeric glucose from its polymeric storage form called glycogen, is a key contributor to hepatic glucose output. Glycogen phosphorylase is the enzyme that catalyzes this process. This review covers advances in the design of small molecule inhibitors of this enzyme, their biological activity, and their potential as effective antihyperglycemic agents for the treatment of Type 2 diabetes.
ISSN:1389-5575
DOI:10.2174/138955706777934991